Anticancer drugs delivered by a new drug delivery system reduce tumor size

August 8, 2018, Osaka University
Outline of the drug delivery system (DDS) created in this study. Credit: Osaka University

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells (CSCs). CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer. However, because CSCs are resistant to chemotherapy and radiotherapy, cancer is refractory.

A research group from Osaka University, in collaboration with Tokyo Institute of Technology, had found that there were CD13 surface markers in hepatocellular carcinoma (HCC) stem cells. When CD13 inhibitor ubenimex is added to CSCs, HCC stem cause apoptosis (programmed cell death), becoming extinct. However, because CSCs only reside in part of tumor tissues, it's imperative to develop a method for delivering drugs in high concentration to target sites.

The researchers created a delivery system (DDS) using a poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate (PEG-b-PLys(Ube)). The use of this DDS has enabled an increase in the concentration of ubenimex in target CSCs. In addition, combined use of standard anticancer drugs significantly decreased CSCs. (Figure 1) Their were published in Oncogene.

Lead author Masamitsu Konno says, "First, we developed a DDS to deliver highly concentrated ubenimex and then, another DDS in which 20 ubenimex molecules were bound with poly ()-poly(lysine) block copolymer conjugates."

Comparative testing: saline solution (control), block copolymer only, block copolymer and ubenimex are administered to mice with hepatic cancer. Days after drug administration and tumor growth in hepatic cancer mice show that hepatic cancer cells significantly reduce in mice that received block copolymer and ubenimex. Credit: Osaka University

Using this method, they performed intraperitoneal administration and intravenous injection of ubenimex in mice, finding that the tumor size was significantly reduced. (Figure 2) This shows that it has become possible to deliver ubenimex to CSCs in high concentration.

Next, the combined administration of ubenimex and existing anticancer drugs (luorouracil (5-FU), cisplatin (CDDP), and doxorubicin (DXR)) was performed, enhancing apoptosis in vitro synergistically in CSCs in mice.

Corresponding author Hideshi Ishii says, "Our research results will promote the application of drugs whose medical effects on CSCs were verified but there were challenges in their delivery to target sites, which will promote repositioning, i.e., the drugs will be used to treat different diseases. Block copolymers used in the DDS in this study can be easily produced and exhibit strong effects, allowing them to be used for the application of other drugs as well."

Explore further: Nanoparticles target and kill cancer stem cells that drive tumor growth

More information: Reishi Toshiyama et al, Poly(ethylene glycol)–poly(lysine) block copolymer–ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells, Oncogene (2018). DOI: 10.1038/s41388-018-0406-x

Related Stories

Nanoparticles target and kill cancer stem cells that drive tumor growth

June 10, 2015
Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs. But now researchers ...

Iron removal as a potential cancer therapy

February 27, 2018
Researchers at Okayama University report in Oncotarget a promising method for targeting cancer stem cells that cause tumor growth and cancer relapse. The approach involves administering molecules that capture iron, an overload ...

Stemming the spread of cancer

September 21, 2012
Okayama University's Masaharu Seno and colleagues have demonstrated in vitro the development of cancer stem cells (CSCs) from a type of normal stem cell exposed to their hypothetical microenvironment of a tumor.

Targeting bladder cancer's Achilles heel: stem cells

January 24, 2018
Two different proteins work separately as well as synergistically to feed a small pool of stem cells that help bladder cancer resist chemotherapy, research led by a Johns Hopkins Kimmel Cancer Center scientist suggests. The ...

HDAC inhibitors show promise against cancer stem cells

October 3, 2016
A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the potential to eliminate ...

Droplet array sheds light on drug-resistant cancer stem cells

May 9, 2012
Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.